(Q39778617)

14 September 2017

title

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population (English)

1 reference

14 September 2017

1 reference

Donna Pauler Ankerst

2

0 references

author name string

Dipen J Parekh

1

1 reference

14 September 2017

Betsy A Higgins

3

1 reference

14 September 2017

Javier Hernandez

4

1 reference

14 September 2017

Edith Canby-Hagino

5

1 reference

14 September 2017

Timothy Brand

6

1 reference

14 September 2017

Dean A Troyer

7

1 reference

14 September 2017

Robin J Leach

8

1 reference

14 September 2017

Ian M Thompson

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

14 September 2017

1 reference

14 September 2017

volume

68

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

1152-1155

1 reference

Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.022

10.1016/J.UROLOGY.2006.10.022

7 January 2021

Identifiers

DOI

1 reference

release_2u7buetrvjg77hrvzsqmhianvu

14 September 2017

Fatcat ID

0 references

1 reference